MELBOURNE, Australia and INDIANAPOLIS, April 22, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces that safety and tolerability data from the ProstACT Global Phase 3 study (Part 1) will be presented as a late-breaking oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026, in Chicago, IL.

ProstACT Global is an international, multi-center, Phase 3 trial evaluating Telix's lead prostate-specific membrane antigen (PSMA) targeted lutetium radio antibody-drug conjugate (rADC) therapy, TLX591-Tx (lutetium-177 (¹⁷⁷Lu) rosopatamab tetraxetan), in combination with standard of care (SoC) versus SoC alone. The study is designed to reflect real-world global clinical practice with the aim to support broad geographic adoption in the evolving prostate cancer treatment landscape.

Part 1 of the trial is a safety and dosimetry lead-in, assessing the tolerability, biodistribution, and radiation dose profile of TLX591-Tx when administered in combination with SoC in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).

The selection of this abstract as a late-breaking oral presentation at ASCO underscores the potential clinical significance of the ProstACT Global study and Telix's continued leadership in advancing next-generation radiopharmaceutical therapies for prostate cancer.